{"version":"1.0","type":"link","title":"Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.","author_name":"Vermeire S 외","author_url":"https://prs-insight.online/author/Vermeire%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/108124","thumbnail_width":1200,"thumbnail_height":630}